The use of temozolomide (TMZ) in combination with inhibition of VEGFR signaling appears to have beneficial effects in the treatment of glioblastomas as TMZ has been shown to reduce the expression of NRP1 and thus induce an increase in treatment cytotoxicity (79). This evidence concerns the gene NRP1 and glioblastoma.